6533b821fe1ef96bd127c33f

RESEARCH PRODUCT

Pharmacokinetics of anidulafungin during venovenous extracorporeal membrane oxygenation

Gerardo AguilarAbigail VillenaRafael FerriolsJosé Miguel AlonsoManuel AlósF. Javier BeldaDavid NavarroJaume PuigJosé A. CarbonellCarlos Ezquer

subject

0301 basic medicineDrugARDSLettermedia_common.quotation_subjectmedicine.medical_treatment030106 microbiologyCritical Care and Intensive Care Medicinelaw.invention03 medical and health sciencesEchinocandins0302 clinical medicinePharmacokineticsRescue therapylawHemofiltrationExtracorporeal membrane oxygenationMedicine030212 general & internal medicinemedia_commonExtracorporeal membrane oxygenationAcute respiratory distress syndromebusiness.industrymedicine.diseaseIntensive care unitAnesthesiaAnidulafunginbusinessmedicine.drug

description

Echinocandins are currently considered the first-line treatment for invasive candidiasis (IC) in the intensive care unit (ICU) [1, 2]. However, extracorporeal membrane oxygenation (ECMO), a rescue therapy used in patients with severe acute respiratory distress syndrome (ARDS) [3], could alter the pharmacokinetics of certain drugs [4]. We prescribed anidulafungin for suspected IC in a patient with severe ARDS on ECMO and measured the plasma concentrations of the drug using high-performance liquid chromatography (HPLC).

yearjournalcountryeditionlanguage
2016-10-17Critical Care
10.1186/s13054-016-1501-4http://europepmc.org/articles/PMC5066289